Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortTwice-yearly infusion for relapsing and primary progressive MS.Highly effective infusion for MS with a risk of PML.
Body systemBrain & NervesBrain & Nerves
Drug classMultiple sclerosis therapiesMultiple sclerosis therapies
SupplyPrescription onlyPrescription only
Main usesRelapsing MS, Primary progressive MSRelapsing MS, Crohn's disease (US)
How it worksRemoves immune B cells that drive MS damage.Stops immune cells from entering the brain.
Starts workingWeeks to monthsWeeks to months
Half-lifeAbout 26 daysAbout 11 days
Typical adult dose300 mg IV twice two weeks apart, then 600 mg every 6 months.300 mg IV once every 4 weeks (every 6 weeks in some regimens).
FormsIV infusion every 6 months, Subcutaneous injection (some regions)Monthly IV infusion
Common side effectsInfusion reactions, Respiratory infections, Herpes infectionsHeadache, Tiredness, Urinary infection, Joint pain
Serious side effectsSerious infections, Hepatitis B reactivation, Possible increase in breast cancer, PML (rare)PML (rare brain infection), Liver injury, Allergic reactions
Don't take ifActive hepatitis B; Active serious infectionActive serious infection; PML history; Immunosuppression
AlcoholUsually no problem in moderation. No known interaction.Usually no problem in moderation. No known interaction.
PregnancyUsually avoidedAvoid unless needed; contraception advised.Use with cautionLimited data; specialist decision.
BreastfeedingUse with cautionLarge antibody; limited data.Use with cautionUnknown amounts in milk.
In use since——
Brand namesUnited States: OcrevusUnited Kingdom: OcrevusIndia: OcrevusUnited States: TysabriUnited Kingdom: TysabriIndia: Tysabri
Legal statusUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule HUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H
ATC codeL04AG08L04AG03

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker